Helena Duani, Alexandro Bonifaz, Andrés Tirado-Sánchez, Vanessa Caroline Randi Magalhães, Max Carlos Ramírez-Soto
{"title":"Sporotrichosis in patients with diabetes mellitus: A systematic review of individual participant data.","authors":"Helena Duani, Alexandro Bonifaz, Andrés Tirado-Sánchez, Vanessa Caroline Randi Magalhães, Max Carlos Ramírez-Soto","doi":"10.1093/mmy/myag060","DOIUrl":null,"url":null,"abstract":"<p><p>Sporotrichosis is a globally distributed subcutaneous mycosis caused by fungi of the Sporothrix complex, and is associated with worse outcomes in immunocompromised individuals, including those with diabetes mellitus. The impact of diabetes mellitus on the clinical presentation and outcomes of sporotrichosis remains poorly characterized. We conducted a systematic review of individual participant data to assess this association. Eight databases (Cochrane Library, Embase, LILACS, MEDLINE/PubMed, Scopus, Global Index Medicus/WHO, SciELO, and Web of Science) were searched without restrictions on publication date, country, language, sex, or age. The retrieved case data were divided into two groups: (1) localized disease and (2) systemic disease. We identified 122 cases of sporotrichosis in patients with diabetes mellitus from 64 articles and from 28 unpublished cases from Brazil and Mexico. Most patients were male (62.3%), with a mean age of 56.6 years, and 73% were from hyperendemic countries. Among cutaneous presentations, lymphocutaneous and fixed cutaneous forms were most frequent (41%), while osteoarticular multifocal disease was the leading extracutaneous manifestation (22.1%). Alcohol use disorder was independently associated with systemic disease (adjusted OR 4.76, 95% CI 1.45-18.05; P = .014). Compared with localized disease, systemic disease more commonly presented with joint symptoms (40.6% vs. 13.5%; P < .001), lesions with lower limb involvement (80% vs. 20%; P < .001), head involvement (81.3% vs. 18.8%; P < .001), and trunk involvement (84.6% vs. 15.4%; P < .001). Itraconazole monotherapy was the main treatment (45.9%), followed by amphotericin B-based regimens (33.6%). There were better outcomes for patients with localized disease than for those with systemic disease (cure rate 86.6% vs. 56.4%; P < .001). Systemic disease carried a 20% mortality rate in this population. These findings underscore the challenges posed by sporotrichosis in patients with diabetes mellitus and highlight the need for further research on risk factors for systemic disease and optimal treatment strategies for this population.</p>","PeriodicalId":18586,"journal":{"name":"Medical mycology","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mmy/myag060","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Sporotrichosis is a globally distributed subcutaneous mycosis caused by fungi of the Sporothrix complex, and is associated with worse outcomes in immunocompromised individuals, including those with diabetes mellitus. The impact of diabetes mellitus on the clinical presentation and outcomes of sporotrichosis remains poorly characterized. We conducted a systematic review of individual participant data to assess this association. Eight databases (Cochrane Library, Embase, LILACS, MEDLINE/PubMed, Scopus, Global Index Medicus/WHO, SciELO, and Web of Science) were searched without restrictions on publication date, country, language, sex, or age. The retrieved case data were divided into two groups: (1) localized disease and (2) systemic disease. We identified 122 cases of sporotrichosis in patients with diabetes mellitus from 64 articles and from 28 unpublished cases from Brazil and Mexico. Most patients were male (62.3%), with a mean age of 56.6 years, and 73% were from hyperendemic countries. Among cutaneous presentations, lymphocutaneous and fixed cutaneous forms were most frequent (41%), while osteoarticular multifocal disease was the leading extracutaneous manifestation (22.1%). Alcohol use disorder was independently associated with systemic disease (adjusted OR 4.76, 95% CI 1.45-18.05; P = .014). Compared with localized disease, systemic disease more commonly presented with joint symptoms (40.6% vs. 13.5%; P < .001), lesions with lower limb involvement (80% vs. 20%; P < .001), head involvement (81.3% vs. 18.8%; P < .001), and trunk involvement (84.6% vs. 15.4%; P < .001). Itraconazole monotherapy was the main treatment (45.9%), followed by amphotericin B-based regimens (33.6%). There were better outcomes for patients with localized disease than for those with systemic disease (cure rate 86.6% vs. 56.4%; P < .001). Systemic disease carried a 20% mortality rate in this population. These findings underscore the challenges posed by sporotrichosis in patients with diabetes mellitus and highlight the need for further research on risk factors for systemic disease and optimal treatment strategies for this population.
孢子菌病是一种全球分布的由孢子菌复合体真菌引起的皮下真菌病,在免疫功能低下的个体(包括糖尿病患者)中与较差的预后相关。糖尿病对孢子虫病的临床表现和预后的影响仍不清楚。我们对个体参与者的数据进行了系统回顾,以评估这种关联。8个数据库(Cochrane Library、Embase、LILACS、MEDLINE/PubMed、Scopus、Global Index Medicus/WHO、SciELO和Web of Science)在没有出版日期、国家、语言、性别或年龄限制的情况下被检索。将检索到的病例数据分为两组:(1)局部疾病和(2)全身性疾病。我们从巴西和墨西哥的64篇文章和28例未发表的病例中鉴定出122例糖尿病患者的孢子虫病。大多数患者为男性(62.3%),平均年龄为56.6岁,73%来自高流行国家。在皮肤表现中,淋巴皮肤和固定皮肤形式最常见(41%),而骨关节多灶性疾病是主要的皮外表现(22.1%)。酒精使用障碍与全身性疾病独立相关(校正OR 4.76, 95% CI 1.45-18.05; P = 0.014)。与局部性疾病相比,全身性疾病更常表现为关节症状(40.6%比13.5%
期刊介绍:
Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.